drugset
drugset / Trial / NCT00107419

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

NCT00107419 ↗

Phase 2 Completed 75 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent and unresectable or metastatic chondrosarcoma.

Timeline

Start
2005-09
Primary completion
2007-05
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

sarcoma